Drugs / Trotabresib
Trotabresib
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06137651 | Dec 2023 → Mar 2024 | breast carcinoma, malignant leptomeningeal tumor, metastatic malignant neoplasm in the brain | Northwestern University | Withdrawn | No outcome recorded |
| Phase 1 | NCT05678283 | Jan 2023 → Apr 2024 | cancer | Bristol-Myers Squibb | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT04324840 | Jul 2020 → Jul 2024 | glioblastoma | Celgene Corporation | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04047303 | Jan 2020 → Jun 2024 | astrocytoma (excluding glioblastoma), glioblastoma | Celgene Corporation | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03220347 | Jul 2017 → Sep 2024 | non-Hodgkin lymphoma | Celgene Corporation | Terminated | No outcome recorded Stop: Business |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trotabresib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06137651 ↗ |
| Known as | Bet inhibitor cc-90010 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650366 ↗ |
| Known as | BMS-986378 | “A Phase I/Ib Trial of Trotabresib (BMS-986378), an Oral BET Inhibitor)” NCT06137651 ↗ |
| Known as | CC-90010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05678283 ↗ |
| Known as | QC-5487 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650366 ↗ |
| Action | Inhibit | “inhibitor of the epigenetic target bromodomain and extra-terminal (BET) proteins” NCT03220347 ↗ |
| Modality | Small molecule | — CHEMBL4650366 ↗ |
| Route | Oral | “CC-90010 is an oral” NCT03220347 ↗ |